Literature DB >> 20212228

New strategies in the management of leptomeningeal metastases.

Morris D Groves1.   

Abstract

The management of patients with leptomeningeal metastases (LM) is multifaceted and complex. Even with an aggressive approach, therapeutic outcomes are uniformly disappointing. This is because of the relentless growth of the central nervous system (CNS) and/or the systemic cancers, or their lethal complications. Advances in the understanding of the homing of cancer cells to the CNS, and of cancer metastasis in general, and more effective anticancer drugs that are adequately delivered to the CNS and cerebrospinal fluid (CSF) are needed to improve outcomes for patients with LM. These advances may lead to better treatments for this disease and, ultimately, its prevention.

Entities:  

Mesh:

Year:  2010        PMID: 20212228     DOI: 10.1001/archneurol.2010.18

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  36 in total

1.  Ventriculoperitoneal shunt for hydrocephalus caused by central nervous system metastasis.

Authors:  Seung Hoon Lee; Doo Sik Kong; Ho Joon Seol; Do-Hyun Nam; Jung-Il Lee
Journal:  J Neurooncol       Date:  2011-01-28       Impact factor: 4.130

2.  Evidence for intrathecal sodium butyrate as a novel option for leptomeningeal metastasis.

Authors:  Hidemitsu Nakagawa; Yoshihiro Yui; Satoru Sasagawa; Kazuyuki Itoh
Journal:  J Neurooncol       Date:  2018-04-06       Impact factor: 4.130

3.  Leptomeningeal metastases.

Authors:  Jordi Bruna; Marta Simó; Roser Velasco
Journal:  Curr Treat Options Neurol       Date:  2012-08       Impact factor: 3.598

4.  Frequent development of leptomeningeal carcinomatosis in patients with peritoneal dissemination of gastric cancer.

Authors:  Shigenobu Emoto; Hironori Ishigami; Hironori Yamaguchi; Hiroharu Yamashita; Shoichi Kaisaki; Joji Kitayama
Journal:  Gastric Cancer       Date:  2011-06-11       Impact factor: 7.370

5.  Leptomeningeal metastasis from solid tumors: a single center experience in Chinese patients.

Authors:  Chunxia Du; Ruoxi Hong; Yuankai Shi; Xiaoduo Yu; Jinwan Wang
Journal:  J Neurooncol       Date:  2013-09-03       Impact factor: 4.130

6.  Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors.

Authors:  Pedro Pérez Segura; Miguel Gil; Carmen Balañá; Ignacio Chacón; José Muñoz Langa; María Martín; Jordi Bruna
Journal:  J Neurooncol       Date:  2012-05-20       Impact factor: 4.130

7.  Leptomeningeal metastasis as initial manifestation of signet ring colorectal adenocarcinoma: a case report with review of literature.

Authors:  Rita Assi; Lana Hamieh; Deborah Mukherji; Ali Haydar; Sally Temraz; Imane El-Dika; Ali Shamseddine
Journal:  J Gastrointest Oncol       Date:  2015-12

8.  Whole brain radiotherapy in management of non-small-cell lung carcinoma associated leptomeningeal carcinomatosis: evaluation of prognostic factors.

Authors:  Yurday Ozdemir; Berna Akkus Yildirim; Erkan Topkan
Journal:  J Neurooncol       Date:  2016-06-15       Impact factor: 4.130

Review 9.  Neoplastic meningitis from solid tumors: new diagnostic and therapeutic approaches.

Authors:  Giuseppe Lombardi; Fable Zustovich; Patrizia Farina; Alessandro Della Puppa; Renzo Manara; Diego Cecchin; Antonella Brunello; Alessandro Cappetta; Vittorina Zagonel
Journal:  Oncologist       Date:  2011-07-27

10.  A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer.

Authors:  E Le Rhun; S Taillibert; F Zairi; N Kotecki; P Devos; A Mailliez; V Servent; L Vanlemmens; P Vennin; T Boulanger; M C Baranzelli; C André; G Marliot; J L Cazin; F Dubois; R Assaker; J Bonneterre; M C Chamberlain
Journal:  J Neurooncol       Date:  2013-03-01       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.